# A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors

> **NCT02222922** · PHASE1 · COMPLETED · sponsor: **Pfizer** · enrollment: 138 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** PF-06647020 Q3W
- **DRUG:** fluconazole
- **DRUG:** PF-06647020 Q2W
- **DRUG:** PF-06647020 combined with Avelumab

## Key facts

- **NCT ID:** NCT02222922
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-17
- **Primary completion:** 2019-11-05
- **Final completion:** 2019-11-05
- **Target enrollment:** 138 (ACTUAL)
- **Last updated:** 2020-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02222922

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02222922, "A Study Of PF-06647020 For Adult Patients With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02222922. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*